Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The introduction of immune checkpoint inhibitors represents a major advance in the treatment of lung cancer, allowing sustained recovery in a significant proportion of patients. Nivolumab is a monoclonal anti–programmed death cell protein 1 antibody licensed for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. In this study, we describe the demographic and clinical outcomes of patients with advanced NSCLC treated with nivolumab in the Korean expanded access program. Materials and Methods Previously treated patients with advanced nonsquamous and squamous NSCLC patients received nivolumab at 3 mg/kg every 2 weeks up to 36 months. Efficacy data including investigator-assessed tumor response, progression data, survival, and safety data were collected. Results Two hundred ninety-nine patients were treated across 36 Korean centers. The objective response rate and disease control rate were 18% and 49%, respectively; the median progression-free survival was 2.1 months (95% confidence interval [CI], 1.87 to 3.45), and the overall survival (OS) was 13.2 months (95% CI, 10.6 to 18.9). Patients with smoking history and patients who experienced immune-related adverse events showed a prolonged OS. Cox regression analysis identified smoking history, presence of immune-related adverse events as positive factors associated with OS, while liver metastasis was a negative factor associated with OS. The safety profile was generally comparable to previously reported data. Conclusion This real-world analysis supports the use of nivolumab for pretreated NSCLC patients, inclu-ding those with an older age.
Abstract
Purpose The introduction of immune checkpoint inhibitors represents a major advance in the treatment of lung cancer, allowing sustained recovery in a significant proportion of patients. Nivolumab is a monoclonal anti–programmed death cell protein 1 antibody licensed for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. In this study, we describe the demographic and clinical outcomes of patients with advanced NSCLC treated with nivolumab in the Korean expanded access program. Materials and Methods Previously treated patients with advanced nonsquamous and squamous NSCLC patients received nivolumab at 3 mg/kg every 2 weeks up to 36 months. Efficacy data including investigator-assessed tumor response, progression data, survival, and safety data were collected. Results Two hundred ninety-nine patients were treated across 36 Korean centers. The objective response rate and disease control rate were 18% and 49%, respectively; the median progression-free survival was 2.1 months (95% confidence interval [CI], 1.87 to 3.45), and the overall survival (OS) was 13.2 months (95% CI, 10.6 to 18.9). Patients with smoking history and patients who experienced immune-related adverse events showed a prolonged OS. Cox regression analysis identified smoking history, presence of immune-related adverse events as positive factors associated with OS, while liver metastasis was a negative factor associated with OS. The safety profile was generally comparable to previously reported data. Conclusion This real-world analysis supports the use of nivolumab for pretreated NSCLC patients, inclu-ding those with an older age.
참고문헌 (23)
- Taube JM, "Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy", Clin Cancer Res, 20, pp.5064~5074 (2014)
- Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
- Brahmer J, "Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer", N Engl J Med, 373, pp.123~135 (2015)
- Gettinger S, "Five-year outcomes from the randomized, phase 3 trials CheckMate 017", 057: nivolumab vs docetaxel in previously treated NSCLC, 2019 (2019), OA14.04~
- Lilenbaum RC, "Prevalence of poor performance status in lung cancer patients : imp-lications for research", J Thorac Oncol, 3, pp.125~129 (2008)
- Sacco PC, "Current challenges of lung cancer care in an aging population", Expert Rev Anticancer Ther, 15, pp.1419~1429 (2015)
- Eisenhauer EA, "New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Rogado J, "Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients", Eur J Cancer, 109, pp.21~27 (2019)
- Sato K, "Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab", Lung Cancer, 115, pp.71~74 (2018)
- Fujii T, "Incidence of immune-related adverse events and its association with treatment outcomes : the MD Anderson Cancer Center experience", Invest New Drugs, 36, pp.638~646 (2018)
- Teraoka S, "Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab : a prospective cohort study", J Thorac Oncol, 12, pp.1798~1805 (2017)
- Haratani K, "Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer", JAMA Oncol, 4, pp.374~378 (2018)
- Shenoy P, "Elderly patients’ participation in clinical trials", Perspect Clin Res, 6, pp.184~189 (2015)
- Grossi F, "Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer : results from the Italian cohort of an expanded access programme", Eur J Cancer, 100, pp.126~134 (2018)
- Assie JB, "Nivolumab outcomes in octogenarian patients with advanced non-small cell lung cancer in a French real-world setting", J Thorac Oncol, 14(10 Suppl), pp.S708~ (2019)
- Soo RA, "Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer : current controversies and future directions", Lung Cancer, 115, pp.12~20 (2018)
- Sakamoto H, "The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations", Mol Clin Oncol, 10, pp.610~614 (2019)
- Li B, "Impact of smoking on efficacy of PD-1", PD-L1 inhibitors in non-small cell lung cancer patients : a meta-analysis, 2018, pp.11, 3691~3696
- Tumeh PC, "Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC", Cancer Immunol Res, 5, pp.417~424 (2017)
- Wang JC, "Cutting edge : CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo", J Immunol, 171, pp.6339~6343 (2003)
- Jenne CN, "Immune surveillance by the liver", Nat Immunol, 14, pp.996~1006 (2013)
- Lee CK, "Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer : a meta-analysis", J Thorac Oncol, 12, pp.403~407 (2017)
- Dong ZY, "EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer", Oncoimmunology, 6, pp.e1356145~ (2017)